|A burning throat, intense neck tenderness|
The fever, sore throat, and progressive neck pain all were worrisome for Lemierre's syndrome. The bacterium typically responsible (a bug called fusobacterium) causes the infected thrombophlebitis of the jugular vein usually within a week of the sore ...
Philly.com - Sun, 01 Dec 2013 00:03
|Ask A Doc: Treatment of varicose veins can vary|
Occasionally, varicose veins can form a painful blood clot with inflammation of the vein called thrombophlebitis. It is estimated that 30 percent to 60 percent of adults have varicose veins. Factors leading to the development of varicose veins include ...
Wausau Daily Herald - Sun, 01 Dec 2013 02:07
|New York Vein Center Launches Campaign on Vein Disease Treatment|
PR Web (press release) - Sun, 01 Dec 2013 00:03
|Venous Insufficiency: Devastating but Curable|
Newsday - Sat, 30 Nov 2013 01:00
|Surgery at St. Elizabeth receives recognition|
The program looks at outcomes related to patient management in nine clinical areas: mortality; unplanned intubation; ventilator for more than 48 hours; renal failure; deep vein thrombosis, thrombophlebitis and pulmonary embolism; cardiac incidents; ...
Utica Observer Dispatch - Mon, 18 Nov 2013 17:03
|BTG plc: FDA Approves Varithena(TM) (Polidocanol Injectable Foam) for the ...|
In clinical trials, the most common related adverse events (occurring in >=3% of patients treated with Varithena(TM)) were pain/discomfort in extremity, infusion site thrombosis (retained coagulum), injection site hematoma or pain, thrombophlebitis ...
Wall Street Journal - Tue, 26 Nov 2013 04:33
The skin injuries can eventually develop into severe tissue damage leading to thrombophlebitis and gangrene. These conditions usually result in limb amputation or sometimes death." Some report the life expectancy of an addict is two years or possibly ...
Martins Ferry Times Leader - Sat, 07 Dec 2013 22:00
|Varicose Vein Dissolver Wins FDA's OK|
Common adverse events in the product's clinical trials included pain or discomfort in the injected leg, infusion site thrombosis, injection site hematoma, superficial thrombophlebitis, and extravasation. Venous thrombosis is a risk of treatment ...
MedPage Today - Tue, 26 Nov 2013 10:56
|BTG plc: FDA Approves Varithena™ (Polidocanol Injectable Foam) for the ...|
PR Newswire (press release) - Tue, 26 Nov 2013 04:30